Noribogaine Reduces Nicotine Self-administration in Rats

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2015 May 22

PMID 25995321

Citations 9

Authors

Qing Chang

Taleen Hanania

Deborah C Mash

Emeline L Maillet

Affiliations

Soon will be listed here.

Abstract

Noribogaine, a polypharmacological drug with activities at opioid receptors, ionotropic nicotinic receptors, and serotonin reuptake transporters, has been investigated for treatment of substance abuse-related disorders. Smoking cessation has major benefits for both individuals and society, therefore the aim of this study was to evaluate the potential of noribogaine for use as a treatment for nicotine dependence. Adult male Sprague-Dawley rats were trained to self-administer nicotine intravenous. After initial food pellet training, followed by 26 sessions of nicotine self-administration training, the rats were administered noribogaine (12.5, 25 or 50 mg/kg orally), noribogaine vehicle, varenicline or saline using a within-subject design with a Latin square test schedule. Noribogaine dose-dependently decreased nicotine self-administration by up to 64% of saline-treated rats' levels and was equi-effective to 1.7 mg/kg intraperitoneal varenicline. Noribogaine was less efficient at reducing food pellets self-administration than at nicotine self-administration, inhibiting the nondrug reinforcing effects of palatable pellets by 23% at the highest dose. These results suggest that noribogaine dose-dependently attenuates drug-taking behavior for nicotine, attenuates the reinforcing effects of nicotine and is comparable to varenicline power in that regard. The findings from the present study hold promise for a new therapy to aid smoking cessation.

Citing Articles

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.

Valdez T, Patel V, Senesombath N, Hatahet-Donovan Z, Hornick M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598395 PMC: 11597566. DOI: 10.3390/ph17111484.

The role of neurotrophic factors in novel, rapid psychiatric treatments.

Kim J, He M, Widmann A, Lee F Neuropsychopharmacology. 2023; 49(1):227-245.

PMID: 37673965 PMC: 10700398. DOI: 10.1038/s41386-023-01717-x.

Acetylglutamine facilitates motor recovery and alleviates neuropathic pain after brachial plexus root avulsion in rats.

Wu L, Chen S, He B, Zhou G, Xu Y, Zhu G J Transl Med. 2023; 21(1):563.

PMID: 37612586 PMC: 10464467. DOI: 10.1186/s12967-023-04399-7.

Sex differences in ethanol consumption and drinking despite negative consequences following adolescent social isolation stress in male and female rats.

McElroy B, Li C, McCloskey N, Kirby L Physiol Behav. 2023; 271:114322.

PMID: 37573960 PMC: 10592127. DOI: 10.1016/j.physbeh.2023.114322.

The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Dalefield M, Scouller B, Bibi R, Kivell B Front Pharmacol. 2022; 13:837671.

PMID: 35795569 PMC: 9251383. DOI: 10.3389/fphar.2022.837671.

References

Pickens C, Cifani C, Navarre B, Eichenbaum H, Theberge F, Baumann M . Effect of fenfluramine on reinstatement of food seeking in female and male rats: implications for the predictive validity of the reinstatement model. Psychopharmacology (Berl). 2011; 221(2):341-53. PMC: 3318998. DOI: 10.1007/s00213-011-2585-9. View

Improgo M, Scofield M, Tapper A, Gardner P . The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog Neurobiol. 2010; 92(2):212-26. PMC: 2939268. DOI: 10.1016/j.pneurobio.2010.05.003. View

Anderson A, Reid M, Li S, Holmes T, Shemanski L, Slee A . Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009; 104(1-2):133-9. PMC: 2818032. DOI: 10.1016/j.drugalcdep.2009.04.015. View

Mash D, Staley J, Baumann M, Rothman R, Hearn W . Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 1995; 57(3):PL45-50. DOI: 10.1016/0024-3205(95)00273-9. View

Benowitz N . Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2008; 49:57-71. PMC: 2946180. DOI: 10.1146/annurev.pharmtox.48.113006.094742. View

Schneider A, Nagel J, Mah S . Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur J Pharmacol. 1996; 317(2-3):R1-2. DOI: 10.1016/s0014-2999(96)00815-1. View

Badio B, Padgett W, Daly J . Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol Pharmacol. 1997; 51(1):1-5. DOI: 10.1124/mol.51.1.1. View

Mash D, Kovera C, Pablo J, Tyndale R, Ervin F, Williams I . Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000; 914:394-401. DOI: 10.1111/j.1749-6632.2000.tb05213.x. View

Hendrickson L, Guildford M, Tapper A . Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013; 4:29. PMC: 3639424. DOI: 10.3389/fpsyt.2013.00029. View

10.

Chatterjee S, Steensland P, Simms J, Holgate J, Coe J, Hurst R . Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology. 2010; 36(3):603-15. PMC: 3055681. DOI: 10.1038/npp.2010.191. View

11.

Changeux J . Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci. 2010; 11(6):389-401. DOI: 10.1038/nrn2849. View

12.

Albuquerque E, Pereira E, Alkondon M, Rogers S . Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009; 89(1):73-120. PMC: 2713585. DOI: 10.1152/physrev.00015.2008. View

13.

Coe J, Brooks P, Vetelino M, Wirtz M, Arnold E, Huang J . Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005; 48(10):3474-7. DOI: 10.1021/jm050069n. View

14.

Alper K, Lotsof H, Frenken G, Luciano D, Bastiaans J . Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999; 8(3):234-42. DOI: 10.1080/105504999305848. View

15.

Maillet E, Milon N, Heghinian M, Fishback J, Schurer S, Garamszegi N . Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology. 2015; 99:675-88. DOI: 10.1016/j.neuropharm.2015.08.032. View

16.

Staley J, Ouyang Q, Pablo J, Hearn W, Flynn D, Rothman R . Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology (Berl). 1996; 127(1):10-8. DOI: 10.1007/BF02805969. View

17.

Olsen C . Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology. 2011; 61(7):1109-22. PMC: 3139704. DOI: 10.1016/j.neuropharm.2011.03.010. View

18.

Obach R, Pablo J, Mash D . Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998; 26(8):764-8. View

19.

Rezvani A, Overstreet D, Yang Y, Maisonneuve I, Bandarage U, KUEHNE M . Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav. 1997; 58(2):615-9. DOI: 10.1016/s0091-3057(97)10003-x. View

20.

Glue P, Lockhart M, Lam F, Hung N, Hung C, Friedhoff L . Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2014; 55(2):189-94. DOI: 10.1002/jcph.404. View